Histone deacetylases modulate resistance to the therapy in lung cancer
Open Access
- 3 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 960263
Abstract
The acetylation status of histones located in both oncogenes and tumor suppressor genes modulate cancer hallmarks. In lung cancer, changes in the acetylation status are associated with increased cell proliferation, tumor growth, migration, invasion, and metastasis. Histone deacetylases (HDACs) are a group of enzymes that take part in the elimination of acetyl groups from histones. Thus, HDACs regulate the acetylation status of histones. Although several therapies are available to treat lung cancer, many of these fail because of the development of tumor resistance. One mechanism of tumor resistance is the aberrant expression of HDACs. Specific anti-cancer therapies modulate HDACs expression, resulting in chromatin remodeling and epigenetic modification of the expression of a variety of genes. Thus, HDACs are promising therapeutic targets to improve the response to anti-cancer treatments. Besides, natural compounds such as phytochemicals have potent antioxidant and chemopreventive activities. Some of these compounds modulate the deregulated activity of HDACs (e.g. curcumin, apigenin, EGCG, resveratrol, and quercetin). These phytochemicals have been shown to inhibit some of the cancer hallmarks through HDAC modulation. The present review discusses the epigenetic mechanisms by which HDACs contribute to carcinogenesis and resistance of lung cancer cells to anticancer therapies.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación
This publication has 125 references indexed in Scilit:
- The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cellsCell Death & Disease, 2013
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapyOncogene, 2011
- Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 AcetylationMolecular Therapy, 2010
- Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase ActivityJournal of Biological Chemistry, 2008
- Clinical and Molecular Responses in Lung Cancer Patients Receiving RomidepsinClinical Cancer Research, 2008
- Bioavailability of Apigenin from Apiin-Rich Parsley in HumansAnnals of Nutrition and Metabolism, 2006
- Substrate Specificity and Kinetic Mechanism of the Sir2 Family of NAD+-Dependent Histone/Protein DeacetylasesBiochemistry, 2004
- Identification of a Signal-Responsive Nuclear Export Sequence in Class II Histone DeacetylasesMolecular and Cellular Biology, 2001
- Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription RepressorJournal of Biological Chemistry, 2000